Kisspeptin Dosage: The Studied Doses and the Circulating Ones
Kisspeptin can stimulate reproductive hormones in people, and the human evidence includes more than intravenous dosing. This guide separates studied fragments and exposure patterns from proposed 100–200 mcg injections a few times weekly. The key is to match the claim to the actual study: a hormone change, an IVF result and a community experience answer different questions. Start with our kisspeptin peptide overview for the biology.
Kisspeptin Dosage Chart
These are research exposures and proposed routines, not interchangeable prescribing instructions. The evidence column is as important as the number.
| Protocol | Dose | Route | Schedule | Evidence |
|---|---|---|---|---|
| Kisspeptin-10, testosterone study | 4 mcg/kg/hour | Continuous IV infusion | 22.5 hours | Published human study in healthy men |
| Kisspeptin-10, bolus | Low mcg/kg range | IV bolus | Single | Dose-ranging LH findings; not a lasting clinical-outcome study |
| Kisspeptin-54, IVF trigger | nmol/kg range | Single subcutaneous | One dose per cycle | Clinical fertility trials |
| Circulating community protocol | 100–200 mcg | Subcutaneous | 2–3x weekly, 4–6 weeks | Not validated by the studies cited here; not equivalent to infusion |
| KP54, hypothalamic amenorrhea | 6.4 nmol/kg | Subcutaneous injection | Twice weekly, eight weeks | Small human hormone study; partial desensitization |
| KP10, 2026 intermittent study | 150 nmol/hour | Subcutaneous infusion | Eight hours on, sixteen off; twelve days | Seven healthy men in this substudy; hormone endpoints |
What Dose Was Actually Studied
The 2011 George study included four healthy men receiving KP10 by continuous IV infusion for 22.5 hours. Its abstract reports mean LH rising from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L, about 45% or approximately 479 to 692 ng/dL. The experiment also included a 3 mcg/kg IV bolus 90 minutes before infusion.
For an 80 kg participant, 4 mcg/kg/hour means 320 mcg/hour and 7.2 mg over the infusion alone, excluding the preceding bolus. That arithmetic describes the experiment; it does not recommend its dose or justify converting it into brief subcutaneous injections.
What Half-Life Does and Does Not Establish
After IV administration, measured plasma half-life was approximately four minutes for KP10 in Jayasena and colleagues' study and 27.6 minutes for KP54 in Dhillo and colleagues' study. Those are IV pharmacokinetic observations, not a measured home-injection duration.
A short plasma half-life does not mean the endocrine response ends at the same instant. Conversely, a brief hormone response does not prove lasting symptom improvement. Human intermittent studies exist, so half-life alone cannot dismiss them; it also cannot validate the proposed twice-weekly KP10 routine.
Kisspeptin-10 vs Kisspeptin-54 Dosing
Both fragments act at the kisspeptin receptor, but their lengths and molecular weights differ. In a 2014 IVF study, 53 women received a single subcutaneous KP54 injection after other ovarian-stimulation medicines. Oocyte maturation and clinical pregnancies were observed. This is a real clinical finding, not an IV-only hormone result, but it belongs to a specialist fertility protocol rather than a stand-alone KP10 regimen.
A molar dose in nmol/kg cannot be copied as a mass dose in mcg, or transferred between fragments without accounting for molecular weight and formulation. A certificate of analysis can inform identity testing; it does not alone establish suitability for human injection. Our research peptides guide explains those documents.
Reconstitution and Dose Math
For arithmetic only, assume 5 mg of peptide in a final solution volume of 2.5 mL: 5000 ÷ 2.5 = 2000 mcg/mL. Then 100 mcg occupies 0.05 mL and 200 mcg occupies 0.1 mL, corresponding to 5 and 10 units on a U-100 scale. At a final volume of 5 mL, the concentration is 1000 mcg/mL and 100 mcg occupies 0.1 mL, or 10 U-100 units. These scale units are volume markings, not biological IU or a count of graduation lines.
The calculation does not establish the correct diluent, sterility, route, dose or beyond-use date. Follow product-specific instructions from the prescriber and dispensing pharmacist rather than assuming bacteriostatic water and refrigeration are universally appropriate. Related background remains in our peptide storage guide, bacteriostatic water guide and how to inject peptides guide; none substitutes for the exact product instructions.
Dosing in Women Is Not the Same Problem
In the cited KP10 sex-comparison study, reproductive-hormone responses depended on menstrual phase: follicular-phase women responded less than preovulatory women and men under the tested conditions. That is a study-specific finding, not a rule that all men respond robustly at every dose or that all women need more.
Diagnosis and cycle context matter when interpreting a result. Fertility treatment needs assessment of outcomes beyond an isolated LH rise, including ovarian response where relevant. Our peptides for fertility guide covers that clinical landscape.
Timing and Cycling
Repeated subcutaneous research is not absent. A 2010 KP54 study in women with hypothalamic amenorrhea found hormone stimulation after eight weeks of twice-weekly injections, with partial desensitization; twice-daily administration produced greater loss of response. The researchers' conference report specifies subcutaneous administration. This does not establish a general four-to-six-week cycle or an optimal fasting window for KP10.
More recently, the August 2026 Yeung study tested KP10 subcutaneous infusion in healthy men. Daily eight-hour infusions, followed by sixteen hours off, sustained gonadotropin and testosterone responses over twelve days. During a separate five-day continuous infusion, testosterone remained elevated but gonadotropins were similar to vehicle. These small studies show why exposure pattern matters; neither is a trial of brief 100–200 mcg injections two or three times weekly. Baseline and follow-up testing can inform clinical assessment, but do not by themselves prove benefit or exclude placebo, natural variation and other treatments. See our testosterone blood test guide.
Safety at These Doses
The 2011 KP10 study and 2010 repeated KP54 study reported no observed adverse effects, an encouraging but limited tolerability finding. Their different populations and exposures should not be pooled informally into a universal safety rate. Research is not limited to single infusions or a few days, but these studies still do not establish safety of months or years of an untested product and schedule.
Reproductive-hormone changes and reduced response with repeated stimulation are observed effects, not purely theoretical possibilities. Their clinical significance depends on the person and treatment goal. Unexpected symptoms or menstrual changes warrant clinical assessment; normal laboratory results are not a safety guarantee. Our peptide side effects guide provides broader context.
Compared With Enclomiphene and hCG
Enclomiphene modifies estrogen feedback and has male hormone dose-ranging studies, including Wiehle and colleagues' phase II trial. hCG activates the LH receptor directly; a testosterone response does not require measured LH to rise. Its clinical pharmacology is described in the Pregnyl prescribing information. These mechanisms and units are different, so they are not dose substitutes.
Kisspeptin research now includes intermittent subcutaneous human studies and specialist KP54 fertility outcomes. That makes a blanket dismissal inaccurate, but does not establish it as the best treatment for an individual. The cause of low testosterone and the fertility goal should drive the comparison. See low testosterone symptoms for diagnostic context.
Bottom Line
Kisspeptin has meaningful human evidence, including IV studies, subcutaneous KP54 fertility research and newer KP10 infusion findings. The proposed brief-injection schedules remain a separate evidence question. Match each result to its fragment, route, population and endpoint; keep concentration arithmetic separate from treatment instructions. Emerging evidence deserves accurate coverage without either a guaranteed-benefit claim or an unsupported claim that it cannot work.
Frequently Asked Questions About Kisspeptin
Human studies use different fragments, routes and schedules; they do not establish a standard community dose. Proposed 100–200 mcg injections two or three times weekly should not be equated with studied infusions. Repeated subcutaneous administration has been researched, including KP54 in women with hypothalamic amenorrhea and KP10 infusion in healthy men.
Measured plasma half-lives after IV administration are about four minutes for KP10 and 28 minutes for KP54. Clearance is not the same as the duration of the downstream hormone response. Half-life alone cannot prove that an intermittent schedule works or fails; fragment, route, exposure pattern and measured outcomes matter.
The 2011 study abstract reports testosterone rising from 16.6 to 24.0 nmol/L during KP10 infusion at 4 mcg/kg/hour for 22.5 hours in four healthy men. A preceding IV bolus was also part of the experiment. This is a small acute hormone study, not a validated home-injection dose or demonstration of sustained clinical benefit.
KP10 and KP54 are different-length peptides acting at the same receptor, with different molecular weights and pharmacokinetics. KP54 has been studied as a subcutaneous IVF trigger; KP10 has also been studied by subcutaneous infusion. Neither the mass dose nor the clinical outcome can simply be transferred between fragments or products.
Preparation is product-specific. For arithmetic only, 5 mg in a final volume of 2.5 mL equals 2000 mcg/mL, so 100 mcg occupies 0.05 mL, or 5 units on a U-100 scale. A final volume of 5 mL gives 1000 mcg/mL, so 100 mcg occupies 0.1 mL, or 10 U-100 units. This does not establish a solvent, sterility, dose, route or storage life.
Responses vary with sex, menstrual phase, fragment and clinical context. The cited KP10 study found a stronger response in men and preovulatory women than in follicular-phase women under the conditions tested. That does not establish one interchangeable dose for every man or woman, nor does a hormone response necessarily show a fertility benefit.
No optimal clock time or fasting routine for proposed brief subcutaneous injections is established by the sources reviewed. Morning or fasting conditions used to standardize a study are not evidence that those conditions improve treatment. The 2026 intermittent infusion study used eight hours on and sixteen off, not a brief morning injection.
Some small monitored human studies reported no observed adverse effects, which is encouraging for those exposures. It does not establish the risk rate of an untested product or long-term regimen. Research includes repeated dosing beyond a few days, but hormone changes, tolerability and clinical benefit remain different endpoints.
Tolerance depends on the specific exposure pattern. KP54 studies in hypothalamic amenorrhea and the 2026 KP10 study show that continuous or frequent stimulation can behave differently from intermittent administration. They do not validate a general four-to-six-week cycle or a receptor-reset break for community injections. Monitoring does not make an untested schedule proven.
Enclomiphene, hCG and kisspeptin act at different points in the reproductive axis. hCG activates the LH receptor rather than needing to raise measured LH; enclomiphene has male hormone dose-ranging data. These are not interchangeable treatments. The diagnosis, fertility goal, product and clinical evidence matter more than which mechanism sounds more upstream.